ASSESSMENT OF SITAGLIPTIN INFLUENCE ON ARTERIAL WALL STIFFNESS, RENAL FUNCTION AND RENAL CIRCULATION IN CARDIOVSCULAR PATIENTS WITH DECOMPENSATED TYPE 2 DIABETES

Aim. To study dynamics of stiffness parameters in various type arteries, renal function and renal circulation in arterial hypertension (AH) and ischemic heart disease (CHD ) with decompensated 2 type diabetes mellitus (DM2) on the sitagliptin therapy during 24 weeks.

Material and methods. Totally 30 patients included, with decompensated DM2 (HbA1c >7%) and AH, most having also CHD. The dynamics of carbohydrate and lipid metabolisms were assessed, arterial wall stiffness in various structural and functional types, renal function and renal circulation at the background of sitagliptine therapy during 24 weeks.

Results. There was no dynamics by the parameters of arterial wall stiffness in various types of arteries, as in renal function and renal circulation among the patients in sitagliptin (n=15) and comparison (n=15) groups. However in those achieved compensation of DM2 on sitagliptin (n=8) we found a decrease of stiffnes index β of brachial artery (muscular type) by 37% from baseline (p<0,01). There was no dynamics of stiffness in muscle-elastic or muscular types of arteries.

Conclusion. In patients with hipertension disease and ischemic heart disease with DM2 on glucoselowering therapy there was no dynamics by the parameters of aortic, common caritid artery stiffness and renal circulation during 6 months followup. However on the therapy by dipeptidilpeptidase-4 inhibitor (sitagliptin) during 6 months and compensation of DM2 (HbA1c <7%) there was a decrease of brachial artery stiffness (muscular type).

1. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulsewave velocity and its relationshipto mortality in diabetes and glucose intolerance: an integrated index of vascular function?Circulation 2002; (106): 2085-90.

2. Cardoso CR, Ferreira MT, Leite NC, et al. Microvascular degenerative complications areassociated with increased aortic stiffness in type 2 diabetic patients. Atherosclerosis 2009;205(2): 472-476. DOI: 10.1016/j.atherosclerosis.

3. Della-Morte D, Ricordi C, Guadagni F, et al. Measurement of subclinical carotidatherosclerosis may help in predicting risk for stroke in patients with diabetes. MetabBrain Dis 2013; 28(3): 337-339. DOI: 10.1007/s11011-013-9385-3.

4. Oskola EV, Shubina AT, Zairova AR, et al. Elastic properties of the vessels, theindicators of renal function and renal blood flow in patients with coronary heart disease,hypertension and related type 2 diabetes. Saharnyj diabet 2014; (3): 96-106. doi:10.14341/DM2014396-106. Russian (Оскола Е. В., Шубина А. Т., Заирова А. Р. и др. Эластические свойства сосудов, показатели функционального состояния почек и почечного кровотока у больных с ишемической болезнью сердца, гипертонической болезнью и сопутствующим сахарным диабетом 2 типа. Сахарный диабет 2014; (3): 96-106. doi: 10.14341/DM2014396-106).

5. Milovanceva-Popovska M, Dzikova S . Progression of diabetic nephropathy: value of intrarenal resistive index (RI). Prilozi 2007; 28(1): 69-79.

6. Hanamura K, Tojo A, Kinugasa S, et al. The resistive index is a marker of renal function, pathology, prognosis, and responsiveness to steroid therapy in chronic kidney disease patients. Int. J. N ephrol 2012; Article ID139565. doi: 10.1155/2012/139565.

7. Matsubara J, Sugiyama S, Sugamura K, еt al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am CollCardiol 2012; 59(3): 265-76.

8. Matsui T, NishinoY, Takeuchi M, еt al. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol. Res 2011; 63(5): 383-8. doi: 10.1016/j.phrs.2011.02.003.

9. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther 2012; 340(2): 248-255. doi: 10.1124/jpet.111.186866.

10. International Diabetes Federation. Chapter 14: Kidney damage. Global Guideline for Type 2 Diabetes 2005; 54-58. Available from: http://www.idf.org/webdata/docs/GGT2D%20 14%20Kidney%20damade.pdf.

11. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; (27): 2588-605.

12. Laurent S, Caviezel B, Beck L, et al. Carotid artery distensibility and distending pressure in hypertensive humans. Hypertension 1994; (23): 878-83.

13. Puttermans T, Nemery C. D iabetes: the use of color Doppler Sonography for the assessment to vascular complications. Eur J Ultrasound 1998; 7(1): 15-22.

14. Dedov II, Shestakova MV, Ametov AS, et al. The consensus of the Board to the Russian Association of Endocrinologists (RAE) for the initiation and intensification of hypoglycemic therapy of type 2 diabetes. Saharnyj diabet 2011; 4: 6-17. Russian (Дедов И . И ., Шестакова М. В., Аметов А. С . и др. Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии СД 2 типа. Сахарный диабет 2011; 4: 6-17).

15. Shubina AT, Demidova IJu, Chernova NA, et al. Metabolic Syndrome X: the possibility of using metformin.Russkij medicinskij zhurnal 2001; 9 (2): 77-81. Russian (Шубина А. Т., Демидова И . Ю., Чернова Н. А. и др. Метаболический синдром Х: возможности применения метформина. Русский медицинский журнал 2001; 9 (2): 77-81).

16. Matikainen N, Taskinen MR. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes. Diabet. Med 2012; 30 (6): 756-7. doi: 10.1111/dme.12094.

17. Emoto M, Nishizawa Y, Kawagishi T, et al. Stiffness indexes beta of the common carotid and femoral arteries are associated with insulin resistance in NIDDM. Diabetes Care 1998; 21(7): 1178-82.

18. Araki T, Emoto M, Teramura M, et al. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metabolism 2006; 55(8): 996-1001.

19. Nagayama D, Saiki A, Endo K, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int. J. Clin. Pract 2010;64(13):1796-1801. doi: 10.1111/j.1742-1241.2010.02399.x.

20. Mason RP, Jacob RF, Kubant R, еt al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J. Atheroscler. Thromb 2011; 18(9): 774-83.

21. Liu L, Liu J, Wong WT, еt al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012; 60(3): 833-41. doi: 10.1161/HYPERTENSIONAHA.112.195115.

22. Andreevskaja MV, Rogoza AN, Saidova MA, et al. Determination of the pulse wave velocity in the aorta using duplex ultrasonography. Kardiologicheskij vestnik 2014; 3: 75-83. Russian (Андреевская М. В., Рогоза А. Н., Саидова М. А. и др. Определение скорости пульсовой волны в аорте с использованием метода ультразвукового дуплексного сканирования. Кардиологический вестник 2014; 3: 75-83).

23. Rjabceva OJu, Orlova JaA, Blankova ZN, et al. The state of the vascular wall in postmenopausal women with hypothyroidism and hypertension. Terapevticheskij arhiv 2013; 10: 64-9. Russian (Рябцева О. Ю., Орлова Я. А., Бланкова З. Н. и др. Состояние сосудистой стенки у женщин в постменопаузе с гипотиреозом и артериальной гипертонией. Терапевтический архив 2013; 10: 64-9).

24. Johansen NB, Charles M, Vistisen D, et al. Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2012; 35(11): 2207-14. doi: 10.2337/dc12-0176.

25. Hattori S . Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J. 2011; 58(1): 69-73.